Notably, in RacET mice, torasemide, reduced the aldosterone synthase-mediated profibrotic signaling limiting the induction of CTGF and LOX, preventing atrial fibrosis and reducing the prevalence of AF [77]. This evidence concerns the gene CCN2 and atrial fibrillation.